Clinical Trial Update: A Phase IIa Study With Escalating Dose of MS1819-SD [Phase 2]

View source ↗

Summary

Phase IIa study of escalating doses of MS1819-SD for chronic pancreatitis and distal pancreatectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Pancreatectomy
• Pancreatitis

Drugs mentioned

• MS1819-SD (MS1819-SD)

Snippet

Sponsor: AzurRx SAS | Conditions: Chronic Pancreatitis, Distal Pancreatectomy | Phase 2 | Status: COMPLETED